The costs for Ozempic and Wegovy injections are being reduced in a limited-time four-month deal, Novo Nordisk announced on Monday.
The introductory price applies only to the lowest strength injections—0.25 mg and 0.5 mg—of Wegovy or Ozempic, lowering the out-of-pocket cost to $199 per month for new self-pay patients between now and March 31, 2026.
Why It Matters
These medications work by lowering blood-sugar levels and are typically used to treat those with type 2 diabetes, but more recently have also been used for weight loss and obesity.
They have become increasingly popular because of their notable impact on a person’s ability to drop weight. Ozempic is Food and Drug Administration (FDA) approved for type 2 diabetes, reducing cardiovascular risk and chronic kidney disease, but not for weight loss, while Wegovy has been approved for weight loss.
However, these medications are typically high-cost, limiting access for many Americans.
What To Know
Novo Nordisk also said in its announcement on Monday that for existing self-pay patients using the injections, costs will also be slashed.
Beginning November 17, the price for existing U.S. self-pay patients (those paying without the help of health insurance) will be reduced from $499 to $349 per month, though the 2 mg Ozempic dose will remain $499.
The introductory $199 price applies for the first two months of treatment, when new self-pay patients will move onto the standard reduced prices of $349 to $499 per month.
These costs will be available to self-pay patients through more than 70,000 pharmacies nationwide, as well as via home delivery and certain telehealth providers.
The Danish company said the offers were partly intended to reduce the appeal of non-FDA-approved compounded semaglutide products.
The update follows the agreement President Donald Trump made with Novo Nordisk and Eli Lilly earlier this month, for patients on Medicare and Medicaid to purchase the GLP-1 drugs at a lower price through a new “TrumpRx” website.
It was reported that the deal would reduce prices for the drugs to between $149 and $350 a month on average for Americans, in the aim of increasing access to the treatments.
Novo Nordisk said that these offers are therefore intended to “expand access to medicines for patients living with obesity and other chronic conditions like diabetes, while lowering prices in the direct-to-patient, self-pay channel in 2026.”
What People Are Saying
Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc said in a statement: “As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them. The U.S. health care system is complex, with different types of insurance and various ways for patients to obtain their medicines.
“Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay. It is part of a larger strategy to expand access that includes building relationships with telehealth providers and major retailers, expanding coverage, and working with the administration to lower costs for people living with chronic diseases like obesity and type 2 diabetes.”
What Happens Next
The introductory offer runs from November 17 through March 31.
